BiotechTube

13-valent Pneumococcal Conjugate Vaccine + 7vPnC + Pediacel + NeisVac-C + Menitorix

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Vaccines, Pneumococcal

Conditions

Vaccines, Pneumococcal

Trial Timeline

Oct 1, 2006 → Oct 1, 2008

NCT ID
NCT00384059

About 13-valent Pneumococcal Conjugate Vaccine + 7vPnC + Pediacel + NeisVac-C + Menitorix

13-valent Pneumococcal Conjugate Vaccine + 7vPnC + Pediacel + NeisVac-C + Menitorix is a phase 3 stage product being developed by Pfizer for Vaccines, Pneumococcal. The current trial status is completed. This product is registered under clinical trial identifier NCT00384059. Target conditions include Vaccines, Pneumococcal.

What happened to similar drugs?

10 of 20 similar drugs in Vaccines, Pneumococcal were approved

Approved (10) Terminated (0) Active (10)
✅Vaxelis™MerckApproved
✅21-valent pneumococcal conjugate vaccineMerckApproved
✅Gardasil-9MerckApproved
✅Human papillomavirus 9-valent vaccine, recombinant + human papillomavirus vaccine, recombinantMerckApproved
✅pneumococcus conjugate vaccine 7 valent to reduce carriagePfizerApproved
✅13vPnCPfizerApproved
✅pneumococcus conjugate vaccinePfizerApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00384059Phase 3Completed

Competing Products

20 competing products in Vaccines, Pneumococcal

See all competitors
ProductCompanyStageHype Score
Vaxelis™MerckApproved
43
21-valent pneumococcal conjugate vaccineMerckApproved
50
Gardasil-9MerckApproved
39
Human papillomavirus 9-valent vaccine, recombinant + human papillomavirus vaccine, recombinantMerckApproved
50
13-valent pneumococcal conjugate vaccine + 7-valent pneumococcal conjugate vaccinePfizerPhase 3
40
13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccinePfizerPhase 3
40
13vPnC + 23vPSPfizerPhase 3
40
13-valent Pneumococcal Conjugate VaccinePfizerPhase 3
40
pneumococcus conjugate vaccine 7 valent to reduce carriagePfizerApproved
43
13-valent Pneumococcal Conjugate Vaccine + 7vPnCPfizerPhase 3
40
rLP2086 + MCV4 + Tdap + MCV4 + Tdap + saline + rLP2086 + salinePfizerPhase 2
35
13 valent pneumococcal conjugate vaccine + 7vPnc pneumococcal conjugate vaccinePfizerPhase 3
40
13vPnCPfizerApproved
43
13-valent pneumococcal conjugate vaccine + 7-valent pneumococcal conjugate vaccine + PentavacPfizerPhase 3
40
pneumococcus conjugate vaccinePfizerApproved
43
13 valent Pneumococcal Conjugate Vaccine + 13 valent Pneumococcal Conjugate Vaccine + 13 valent Pneumococcal Conjugate Vaccine + 23-valent Pneumococcal Polysaccharide Vaccine + 23-valent Pneumococcal Polysaccharide VaccinePfizerPhase 3
40
Prevenar + Infanrix hexaPfizerApproved
43
13-valent Pneumococcal Conjugate VaccinePfizerPhase 2
35
13vPnCPfizerApproved
43
13 valent pneumococcal conjugate vaccine with Polysorbate 80 + 13 valent pneumococcal conjugate vaccine without Polysorbate 80PfizerPhase 3
40